Factor Bioscience Inc., a Cambridge -based biotechnology company focused on developing mRNA and cell-engineering technologies, announced its participation in the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting to be held in Washington, D.C. from May 16-19, 2022.
-Factor to reveal mRNA-based iPS cell-derived macrophages for solid-tumor targeting, allogeneic iPS cell-derived cytotoxic lymphocytes, and advanced targeted insertion technologies CAMBRIDGE, Mass., May 16, 2022 /PRNewswire/ -- Factor BioscienceInc., a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies, announced its participation in the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting to be held in Washington, D.C. from May 16-19, 2022, at which Factor will deliver four presentations: Factor to reveal mRNA-based iPS cell-derived macrophages for solid-tumor targeting
Digital presentations will be made available on the ASGCT website on May 16, 2022. For more information about the American Society of Genetic & Cell Therapy (ASGCT) Annual Meeting, visit https://annualmeeting.asgct.org. About Factor Bioscience
SOURCE Factor Bioscience |